Efficacy and Safety of Aspirin-free versus Aspirin-based Strategies in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

内容摘要

Aspirin (ASA) is the cornerstone of the acute coronary syndrome primary and secondary prevention. Still, its role is debated in some high bleeding risk patients or cases that underwent second-generation drug-eluting stents with a better scaffold. This study compared the efficacy and safety of aspirin-free versus aspirin-based strategies in patients with ACS undergoing PCI. We systematically searched PubMed, Embase, Scopus, and ScienceDirect for studies comparing aspirin-based versus aspirin-free strategies in patients with ACS undergoing PCI. Pooled relative risk (RR) with 95% CI was calculated using a fixed effects model or a random effects model if heterogeneity was present. Significance was set at P < 0.05. Thirty studies including 207,938 patients (N = 104,062 in the ASA arm, and 103,876 in the ASA-free arm) were included in this study. There was a statistically significant reduction in risk of all-cause mortality [RR 0.93, 95% CI, 0.87-0.99, P-value = 0.024, I2 = 0%], BARC 2-5 [RR = 0.68, 95% CI, 0.58-0.81, P-value = <0.01, I2 = 0%], BARC 3 or 5 [RR= 0.71, 95% CI, 0.60-0.82, P-value= <0.01, I2 = 0%], TIMI major bleeding [RR = 0.66, 95% CI, 0.50-0.86, P-value= 0.02, I2 = 0%], TIMI minor or major bleeding [RR= 0.61, 95% CI, 0.52-0.72, P-value= <0.01, I2 = 0%], and ISTH major bleeding with aspirin-free strategy [RR= 0.52, 95% CI, 0.42-0.64, P-value= <0.001, I2= 0%]. Other secondary outcomes showed statistically nonsignificant results. The aspirin-free strategy showed lower all-cause mortality and bleeding, supporting its efficacy and safety in high bleeding risk patients.